Literature DB >> 20092693

Quality of life and motor impairment in ALS: Italian validation of ALSAQ.

A Palmieri1, G Sorarù, L Lombardi, C D'Ascenzo, L Baggio, M Ermani, E Pegoraro, C Angelini.   

Abstract

OBJECTIVES: To evaluate the validity and reliability of the amyotrophic lateral sclerosis assessment questionnaire (ALSAQ) in an Italian cohort of ALS patients and to further characterize the relationship between motor impairment and quality of life (QoL) in ALS.
METHODS: Seventy-six patients completed the Italian version of ALSAQ-40 and ALSAQ-5. To verify test-retest reliability, 30 patients were revaluated after 3 months. The medical outcome study short form 36 (MOS SF-36) questionnaire and revised ALS functional rating scale (ALSFR-R) scale were used to assess Italian ALSAQ-40 construct validity. The limb muscles' Medical Research Council (MRC) score and forced vital capacity (FVC) were used to measure the degree of motor impairment.
RESULTS: The Italian ALSAQ-40 showed a very good internal consistency (all subscales Cronbach's alpha>0.86) and a good construct validity as shown by the patterns of correlation between the subscales and SF-36 (resp. ALSFRS-R) scores. ALSAQ-5 showed a positive correlation with the corresponding ALS patient total score and subscale scores of the ALSAQ-40 (Spearman's correlation coefficient>0.73). The emotional functioning subscale did not correlate with any motor impairment measures. DISCUSSION: Italian ALSAQ-40 and ALSAQ-5 psychometric properties are reliable and similar to those showed by the original English version. We observed emotional aspects to be distinct from physical involvement.

Entities:  

Mesh:

Year:  2010        PMID: 20092693     DOI: 10.1179/174313209X385734

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  7 in total

Review 1.  Diagnostics of Amyotrophic Lateral Sclerosis: Up to Date.

Authors:  Ivana Štětkářová; Edvard Ehler
Journal:  Diagnostics (Basel)       Date:  2021-02-03

2.  Efficacy of hypnosis-based treatment in amyotrophic lateral sclerosis: a pilot study.

Authors:  Arianna Palmieri; Johann Roland Kleinbub; Vincenzo Calvo; Gianni Sorarù; Irene Grasso; Irene Messina; Marco Sambin
Journal:  Front Psychol       Date:  2012-11-05

3.  Hypnosis-based psychodynamic treatment in ALS: a longitudinal study on patients and their caregivers.

Authors:  Johann R Kleinbub; Arianna Palmieri; Alice Broggio; Francesco Pagnini; Enrico Benelli; Marco Sambin; Gianni Sorarù
Journal:  Front Psychol       Date:  2015-06-16

4.  A Nation-Wide, Multi-Center Study on the Quality of Life of ALS Patients in Germany.

Authors:  Tara Peseschkian; Isabell Cordts; René Günther; Benjamin Stolte; Daniel Zeller; Carsten Schröter; Ute Weyen; Martin Regensburger; Joachim Wolf; Ilka Schneider; Andreas Hermann; Moritz Metelmann; Zacharias Kohl; Ralf A Linker; Jan Christoph Koch; Boriana Büchner; Ulrike Weiland; Erik Schönfelder; Felix Heinrich; Alma Osmanovic; Thomas Klopstock; Johannes Dorst; Albert C Ludolph; Matthias Boentert; Tim Hagenacker; Marcus Deschauer; Paul Lingor; Susanne Petri; Olivia Schreiber-Katz
Journal:  Brain Sci       Date:  2021-03-14

5.  A Telehealth Intervention for Nutritional Counseling in Amyotrophic Lateral Sclerosis Patients.

Authors:  Fabiola De Marchi; Marcella Serioli; Alessandro Collo; Evelyn Gisell Belotti; Francesca Alloatti; Giampaolo Biroli; Andrea Bolioli; Roberto Cantello; Sergio Riso; Letizia Mazzini
Journal:  J Clin Med       Date:  2022-07-23       Impact factor: 4.964

6.  Self perceived emotional functioning of spanish patients with amyotrophic lateral sclerosis: a longitudinal study.

Authors:  Jesús S Mora; Teresa Salas; María L Fajardo; Lourdes Iváñez; Francisco Rodríguez-Santos
Journal:  Front Psychol       Date:  2013-01-08

7.  A systematic review of non-motor symptom evaluation in clinical trials for amyotrophic lateral sclerosis.

Authors:  Emily Beswick; Deborah Forbes; Zack Hassan; Charis Wong; Judith Newton; Alan Carson; Sharon Abrahams; Siddharthan Chandran; Suvankar Pal
Journal:  J Neurol       Date:  2021-06-13       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.